Schizophrenia News and Research

Latest Schizophrenia News and Research

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Vanda Pharmaceuticals Inc. announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults.

14 Oct 2009

Positive results from Alkermes' ALKS 33 clinical trials announced

Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.

13 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Cochlear implant inventor chosen for neuroscience research

Dr. Michael Merzenich, PhD - renowned neuroscientist, university professor, cochlear implant inventor, brain plasticity expert and tech entrepreneur - was formally inducted in the Institute of Medicine (IOM) today in Washington, D.C.

13 Oct 2009

Mechanism by which gene associated with autism and schizophrenia influences behavior identified

A Stanford University School of Medicine researcher has pinpointed the mechanism by which a gene associated with both autism and schizophrenia influences behavior in mice. And just recently, he received a $1.65 million government grant to expand his efforts to include many more such genes.

13 Oct 2009

Vanda Pharmaceuticals' Fanapt to be commercialized in the U.S. and Canada by Novartis Pharma

Titan Pharmaceuticals, Inc today announced that Vanda Pharmaceuticals, Inc. reported its entry into an exclusive agreement with Novartis Pharma AG to commercialize and develop Fanapt™ (iloperidone) in the U.S. and Canada. Fanapt™, an atypical anti-psychotic, was approved by the U.S. Food and Drug Administration earlier this summer for the acute treatment of schizophrenia in adults.

13 Oct 2009

CED to host popular STREAK program

CED, formerly the Council for Entrepreneurial Development (www.cednc.org), a private, nonprofit organization that promotes entrepreneurial efforts in the Triangle region of North Carolina, has announced that it will host the next installment of its popular STREAK program, to be held Thursday, Oct. 8 from 3 p.m. to 5 p.m.

12 Oct 2009

Study finds that stranger homicide by people with schizophrenia rare

International study led by Sydney researchers shows homicides of strangers by people with schizophrenia are exceptionally rare and unpredictable events

12 Oct 2009

Homicides of strangers by people with schizophrenia are exceptionally rare, says study

International study led by Sydney researchers shows homicides of strangers by people with schizophrenia are exceptionally rare and unpredictable events

12 Oct 2009

WCMC-Q program highlights the importance of mental health to overall physical health

Mental health professionals from Weill Cornell Medical College in Qatar and the community highlighted the importance of mental health to overall physical health during a presentation Sunday as part of the medical college's recognition of World Mental Health Day.

12 Oct 2009

Three hundred participants sought for world-first study to determine shared biological basis for psychotic illnesses

For the first time, sufferers of schizophrenia and bipolar disorder are being brought together in a major new study investigating the diseases' common genetic causes and manifestations.

11 Oct 2009

CHFA awards two individuals for their contributions in natural and organic products industry

The natural health and organic products industry recognized the achievements of individuals committed to the growth of the sector in an awards presentation at the Canadian Health Food Association's (CHFA), Expo East, October 2-4, 2009.

8 Oct 2009

Aryx Therapeutics to raise up to $35 million from sale of its common stock

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has secured a committed equity financing facility under which it may sell up to $35 million of shares of its common stock to Commerce Court Small Cap Value Fund, Ltd. (“Commerce Court”) over a 24 month period. The maximum number of shares that can be sold by ARYx is specified in the agreement. ARYx is not obligated to utilize any of the $35 million facility and remains free to enter into and consummate other equity and debt financing transactions.

7 Oct 2009

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.

7 Oct 2009

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

A new treatment option for Canadians with schizophrenia, ABILIFY(TM) (aripiprazole), is now available in Canada. For those living with this lifelong disease who may be struggling with a treatment that doesn't work for them or with side effects that are difficult to tolerate, ABILIFY offers efficacy and good safety and tolerability with limited impact on weight, blood sugar and lipids - significant clinical benefits that may help patients stay on treatment longer.

6 Oct 2009

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (“Biovail”), a subsidiary of Biovail Corporation.

6 Oct 2009

NIH awards Galenea a Challenge Grant for developing predictive in vivo models of cognition

Galenea Corp., a fully-integrated CNS drug discovery company, announced today that it has been awarded an NIH Challenge Grant in Health and Science Research (RC1) as part of the American Recovery and Reinvestment Act of 2009 (Recovery Act). This two-year grant from the National Institute of Mental Health addresses the specific topic of "Screening Approaches to Identify Pharmacologic Treatments for Mental Disorders" within the challenge area of Translational Science.

6 Oct 2009

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

GVK Biosciences (GVK BIO), Asia’s leading integrated research services provider and Quantitative Solutions (QS), a modeling and simulation (M&S) consultancy to the pharmaceutical and biotech industry, announced a strategic partnership to develop and market clinical trial outcome databases.

5 Oct 2009

Study shows that GSK-3 gene determines the total number of neurons required for brain

In populating the growing brain, neural stem cells must strike a delicate balance between two key processes - proliferation, in which the cells multiply to provide plenty of starting materials - and differentiation, in which those materials evolve into functioning neurons.

5 Oct 2009

NIMH awards USC scientists $9M for mapping gene expression during human brain development

Two University of Southern California (USC) neuroscientists have been awarded nearly $9 million in American Recovery and Reinvestment Act funds to map how genes are expressed in different regions of the human brain throughout development.

3 Oct 2009

Schizophrenia News and Research

Latest Schizophrenia News and Research

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Positive results from Alkermes' ALKS 33 clinical trials announced

Johnson & Johnson announces financial results for the third quarter of 2009

Cochlear implant inventor chosen for neuroscience research

Mechanism by which gene associated with autism and schizophrenia influences behavior identified

Vanda Pharmaceuticals' Fanapt to be commercialized in the U.S. and Canada by Novartis Pharma

CED to host popular STREAK program

Study finds that stranger homicide by people with schizophrenia rare

Homicides of strangers by people with schizophrenia are exceptionally rare, says study

WCMC-Q program highlights the importance of mental health to overall physical health

Three hundred participants sought for world-first study to determine shared biological basis for psychotic illnesses

CHFA awards two individuals for their contributions in natural and organic products industry

Aryx Therapeutics to raise up to $35 million from sale of its common stock

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

NIH awards Galenea a Challenge Grant for developing predictive in vivo models of cognition

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

Study shows that GSK-3 gene determines the total number of neurons required for brain

NIMH awards USC scientists $9M for mapping gene expression during human brain development

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Schizophrenia News and Research

Latest Schizophrenia News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in